By leveraging omics technologies, epidemiologists can uncover the genetic, proteomic, and metabolic underpinnings of disease. For instance, genome-wide association studies (GWAS) can identify genetic variants associated with disease risk. Proteomic analyses can reveal biomarkers for early detection, while metabolomic studies can identify metabolic pathways altered in disease states. These insights are invaluable for developing targeted therapies and personalized medicine.
